TrialMed (New York, N.Y.)2025

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial.

Anna Brandt et al.PubMed ↗Publisher ↗

No numbers read from the abstract.